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Abstract
Background: Exposure of cancer cells to chemotherapeutic agents may result in reduced sensitivity to structurally 
unrelated agents, a phenomenon known as multidrug resistance, MDR. The purpose of this study is to investigate cell 
growth inhibition of wild type and the corresponding MDR cells by Tumor Treating Fields - TTFields, a new cancer 
treatment modality that is free of systemic toxicity. The TTFields were applied alone and in combination with paclitaxel 
and doxorubicin.
Methods: Three pairs of wild type/MDR cell lines, having resistivity resulting from over-expression of ABC transporters, 
were studied: a clonal derivative (C11) of parental Chinese hamster ovary AA8 cells and their emetine-resistant sub-line 
EmtR1; human breast cancer cells MCF-7 and their mitoxantrone-resistant sub lines MCF-7/Mx and human breast 
cancer cells MDA-MB-231 and their doxorubicin resistant MDA-MB-231/Dox cells. TTFields were applied for 72 hours 
with and without the chemotherapeutic agents. The numbers of viable cells in the treated cultures and the untreated 
control groups were determined using the XTT assay. Student t-test was applied to asses the significance of the 
differences between results obtained for each of the three cell pairs.
Results: TTFields caused a similar reduction in the number of viable cells of wild type and MDR cells. Treatments by 
TTFields/drug combinations resulted in a similar increased reduction in cell survival of wild type and MDR cells. 
TTFields had no effect on intracellular doxorubicin accumulation in both wild type and MDR cells.
Conclusions: The results indicate that TTFields alone and in combination with paclitaxel and doxorubicin effectively 
reduce the viability of both wild type and MDR cell sub-lines and thus can potentially be used as an effective treatment 
of drug resistant tumors.
Background
Multidrug resistance (MDR) [1] is encountered when
cancer cells are exposed to chemotherapeutic agents for a
few replication cycles. It is manifested in reduced sensi-
tivity to both the specific chemotherapy as well as to a
number of structurally unrelated agents. This phenome-
non obviously poses a serious impediment to successful
chemotherapy. Three decades of multidrug resistance
research have identified a number of mechanisms by
means of which cancer cells elude the effects of chemo-
therapeutic agents. The most often encountered MDR is
the one resulting from over-expression of ATP-binding
cassette transporters such as P-glycoprotein (MDR1),
multidrug resistance-associated protein-1 (MRP1), and
the breast cancer resistance protein (BCRP) [1-3]. These
transporters, that recognize substrates of diverse chemi-
cal nature, lower the intracellular concentration of these
substrates and are normally involved in detoxification
[4,5].
MDR can potentially be overcome by the use of antitu-
mor modalities that are not involved in membrane trans-
port, for example, anti-angiogenic agents and physical
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Different types of electric fields were reported to inhibit
cancer cell proliferation and cause cancer cell destruc-
tion, for example: exposure of cancer cells to low ampli-
tude DC currents [6], low intensity, low frequency (50
Hz) AC currents [7] and the intermediate frequency (100-
300 kHz) alternating electric fields, termed TTFields [8-
12].
TTFields are a new physical cancer treatment modality
that has recently been demonstrated to be highly effective
when applied to cell cultures, animal cancer models, as
well as patients suffering from locally advanced and/or
metastatic solid tumors [8-12]. TTFields are alternating
electric fields of low intensity (1-3 V/cm) and intermedi-
ate frequency (100 - 300 kHz) that are generated by spe-
cial insulated electrodes applied to the skin surface.
These specially tuned fields have no effect on quiescent
cells while having an anti-proliferation and destructive
effect on mitotic cells. This effect is due to the fact that
during cytokinesis, TTFields exert forces that move
charged or polar macromolecules and organelles towards
the narrow neck, separating the newly forming daughter
cells [8,9]. They also interfere with the polymerization
processes of the microtubule spindle during cell division.
Thus, TTFields disrupt the cell structure, inhibit cell divi-
sion and result in cell death. In contrast to most anti-can-
cer agents, TTFields are not associated with any
meaningful systemic toxicity [9-12]. Furthermore, it was
recently shown that TTFields may be used clinically, not
only as an anti-proliferation agent, but also as effective
adjuvant to currently used chemotherapeutic agents [9].
In view of the above, the target of the present study was
to test the possibility of using TTFields for treating multi-
drug resistant cancerous and non cancerous cell lines,




All cell culture media, serum and media supplements
were obtained from Biological Industries, Beth Haemek,
Israel. All drugs and chemical agents were obtained from
Sigma.
Cell lines
The following cell lines and their drug resistant deriva-
tives were used: A clonal derivative (C11) of parental Chi-
nese hamster ovary AA8 cells and their emetine-resistant
sub-lines EmtR1 cells having ATP dependent MDR1 type
drug resistance [13], a kind gift from Prof. G. Eytan Dept.
of Biology, Technion, Haifa, Israel; Human breast cancer
wild type MCF-7 cells, obtained from ATCC and their
mitoxantrone-resistant sub-lines MCF-7/Mx having
ABCG2 transporter [14], a kind gift from Prof. M. Lisco-
vitch, Dept. of Biological Regulation Weizmann Institute
of Science, Rehovot, Israel; Human breast cancer wild
type MDA-MB-231 cells obtained from ATCC and from
which doxorubicin resistant MDA-MB-231/Dox cells
were developed in our laboratory using a stepwise
increase in drug concentration protocol. This procedure
is identical with that developed for these cells in other
laboratories [15] for inducing MDR1 type of ABC trans-
porters. The AA8/EmtR1 cell lines were maintained as a
monolayer in -minimal essential medium containing 5%
fetal calf serum, 2 mM glutamine, 100 units/ml penicillin
G, and 100 μg/ml streptomycin sulphate. The EmtR1 cell
medium also included 1 μM of emetine. The MCF-7/
MCF-7MX and MDA-MB-231/MDA-MB-231Dox cell
lines were maintained under monolayer conditions in
DMEM containing 10% fetal calf serum, 2 mM glutamine,
100 units/ml penicillin G, and 100 μg/ml streptomycin
sulphate. The MCF-7/Mx cell medium also included 250
nM of mitoxantrone and the MDA-MB-231/Dox cells
medium also included 0.1 μM of doxorubicin.
All cells were kept in a 5% CO2 incubator at 37°C. Expo-
nentially growing cells were passaged twice a week using
a standard trypsinization procedure.
Cytotoxicity assay
The level of resistance to doxorubicin and paclitaxel was
determined by means of the XTT assay as previously
described [8,9]. Briefly, 2 × 104 cells/well were plated in
24-well plate (NUNC), incubated without drugs for 24 h
and then the initial number of cells, OD0, was determined
following incubation of with the XTT reagent using
ELISA Reader (TECAN Sunrise, USA). The medium was
then exchanged with ones containing different drug con-
centrations, 4 wells for each drug concentration (doxoru-
bicin: 0.001-100 μM; paclitaxel: 0.0001-100 μM). After 72
h, the culture media was discharged, XTT reagent was
added and the final cell number, OD72 h, was determined.
Data obtained from 3 - 5 experiments were collected and
the mean values and standard deviations (SEM) of OD72
h, representing final number of viable cells, were calcu-
lated for each drug concentration. Cell survival was pre-
sented as percentage of viable cells as compared to the
corresponding viable cell number in no - drug controls.
Drug concentrations inhibiting cell growth by 50% (IC50)
were calculated from relative survival curves using the
median-effect principle [16].
Exposure to TTFields
As previously described [9,11], two pairs of electrodes,
insulated by a ceramic having a very high dielectric con-
stant (NovoCure Ltd, Haifa, Israel), were positioned at 90°
with respect to each other in both treatment and control
Petri dishes. The distance between the electrodes in each
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connected for 250 ms to a sinusoidal waveform generator
(NovoTTF, NovoCure Ltd. Haifa, Israel) that produced
1.75 V/cm, 150 kHz fields in the medium [8]. The 150
kHz frequency of TTFields was found to be effective for
treatment of all cells studied.
Four different sets of conditions in each experiment
were conducted for each cell line in conjunction with
each chemotherapeutic agent: untreated control cells,
cells treated by the chemotherapeutic agent alone, cells
exposed to TTFields, and cells having a combined
TTFields - Chemo exposure (8 Petri dishes for each con-
dition). After 72 h, the culture media was discharged,
XTT reagent was added and the final number of viable
cells, OD72 h, was determined. Data obtained from 3 - 5
experiments were collected and the mean values and
standard deviations (SEM) of OD72 h, representing final
viable cell numbers were calculated for each set of condi-
tions. Cell survival was presented as percentage of viable
cells out of the corresponding viable cell number in
untreated controls. Student t-test was applied to asses the
significance of the differences between results obtained
for each of the four conditions tested. In order to assess
the extent of possible chemotherapeutic dose reduction
when applied in combination with TTFields, dose reduc-
tion indexes (DRI) for each TTFields/drug combination
were calculated according to [17].
The DRI for the same level of effect (DRIm) was calcu-
lated as the ratio of the concentration of drug alone to
that of the combined drug-TTFields treatment:
DRIm = Dm(drug alone)/Dm(combined treatment). The DRIs
determine the magnitude of dose reduction allowed for
each drug when given in combination with TTFields, as
compared with the agent dose that achieves the same
level of effect. DRI values larger than 1 indicate increased
sensitivity to the drug.
Intracellular Doxorubicin Accumulation
The intracellular accumulation of doxorubicin was deter-
mined for both wild type and drug resistant sub-lines.
Cells were grown in total 16 Petri dishes (35 mm, NUNC)
as monolayers for 24 h in drug-free medium and then
incubated for 1 h in the absence or presence of doxorubi-
cin with or without exposure to TTFields (1.75 V/cm, 150
kHz) (4 Petri dishes for each treatment condition). The
cells were washed with ice cold PBS three times and solu-
bilised with 100 μl of 2% SDS. The solutions were then
transferred to black 96-well plates (NUNC) and doxoru-
bicin fluorescence was measured by spectrofluorometry
(ELISA Reader TECAN F-200) at λem 600 nm and λex 450
nm. Data obtained from 2 - 4 experiments were collected
and the mean values and standard deviations (SEM) of
doxorubicin fluorescence were calculated for each condi-
tion. Student t-test was applied to asses the significance
of the differences between results obtained for each of the
three cell pairs.
Results
Effect of TTFields on wild type cells and their MDR sub-lines
In order to study the TTFields effect, field intensities that
reduce the WT cell survival by about 50% were used. A
comparison between the survival of wild type and MDR
cells, when exposed to such TTFields, is given in Figure 1.
The reduction in the number of viable cells is seen to be
very similar (48-61% of control) in all wild type and
paired MDR lines. In other words, the drug resistant cell
lines have about the same sensitivity to TTFields as their
corresponding wild type cell lines.
Exposure to doxorubicin or paclitaxel in combination with 
TTFields
Figure 2 compares between the cytotoxicity-dose curves
of chemotherapeutic agents (paclitaxel and doxorubicin)
of wild type cells and MDR sub-lines. It is seen that the
resistivity of the MDR sub-lines is manifested in a signifi-
cant right shift of the drug cytotoxicity-dose curves. As a
result of these shifts the calculated IC50 values (Table 1)
for doxorubicin and paclitaxel, for all pairs of WT-MDR
cell lines studied, give very high IC50 ratios (resistance
index RI): 55 - 79 for doxorubicin and 128 - 653 for pacli-
taxel.
A comparison between cell viability following separate
and combined TTFields/drug exposures are presented in
Figure 3. It is seen that in all combined exposures cell sur-
vival is lower as compared with exposure to any of the
Figure 1 The reduction in the number of viable WT and MDR cells 
following a 72 h exposure to TTFields. Open bars - WT cells; filled 
bars - MDR cell sub-lines. TTFields intensity - 1.75 V/cm. Data presented 
as mean ± SEM of 30-36 replicate measurements from 4-5 experi-
ments. Note that there is no statistical difference between WT and 
MDR pairs (student t-test).
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alone (see Figure 1). Moreover, the cell survival of the
MDR sub-lines and WT cell lines, when subjected to the
combined exposure is similar, i.e. the resistivity or
reduced drug sensitivity of MDR cells are not evident
under these conditions.
Table 2 summarizes the combined treatment efficacy
for MDR cells (see Figures 2 &3) expressed in terms of
Dose Reduction Index (DRI). TTFields are seen to
increase the sensitivity to doxorubicin of all three MDR
sub-lines by at least two orders of magnitude. The corre-
sponding increase for paclitaxel is even greater, i.e. two to
three orders of magnitude. In other words, the efficacy of
combined drug/TTFields treatment of MDR cells greatly
exceeds that of treatment with drug alone.
Intracellular Doxorubicin Accumulation
An inherent feature of overexpressed ABC transporters
phenotype is the reduction in cell uptake of doxorubicin
due to its exclusion [18]. The ability of MDR cells to
exclude doxorubicin was determined by means of spec-
trofluorometric analysis. Figure 4A illustrates the intrac-
Figure 2 Cytotoxicity of doxorubicin and of paclitaxel for wild type cells and the corresponding MDR sub-line cells. A, B & C - doxorubicin. D, 
E & F - paclitaxel. A & D - AA8 & EmtR1 cell lines; B & E - MCF-7 & MCF-7/Mx cell lines; C & F - MDA-MB-231 & MDA-MB-231/Dox cell lines. Open symbols 
-wild type cell lines. Filled symbols - MDR cell sub-lines. Treatment duration - 72 h. Data presented as mean ± SEM of 12-20 replicate measurements 
from 3-5 experiments.
Table 1: IC50 values for doxorubicin and paclitaxel
IC50
Drug AA8 EmtR1 MCF-7 MCF-7/Mx MDA-MB-231 MDA-MB-231/Dox
Doxorubicin (μM) 0.6 48.4 0.5 30.5 0.04 2.2
Paclitaxel (μM) 0.1 65.3 0.09 9.9 0.005 0.829
Drug concentrations inhibiting cell growth by 50% (IC50) were calculated from relative survival curves (see Figure 2) using the median-effect 
principle [16].
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EmtR1 (MDR) cell lines as a function of extracellular dox-
orubicin concentration with and without exposure to
TTFields. As the drug is partially excluded from drug
resistant sub line, the relative intracellular doxorubicin
concentration in EmtR1 cells is lower by 44.9, 49.7 and
49.8% at 15, 30 and 45 μM extracellular doxorubicin con-
centration respectively, as compared with the wild type
cells (Figure 4A, open symbols). Exposure of AA8 (WT)
and EmtR1 (MDR) cell lines to TTFields during incubation
with doxorubicin had no effect on the intracellular con-
centration of the drug in both wild type and drug resis-
tant sub lines indicating that TTFields affect neither
doxorubicin uptake nor its exclusion (Figure 4A, filled
symbols). Figure 4B depicts doxorubicin accumulation by
MDR sub lines relative to the corresponding WT cell
lines exposed to 30 μM of doxorubicin with and without
TTFields. The relative intracellular doxorubicin concen-
tration is lower by 49.7 ± 5% for EmtR1, 66.4 ± 5% for
MCF-7/Mx and by 32.6 ± 5% for MDA-MB-231/Dox as
compared with the corresponding wild type cells (Figure
4B, open bars). TTFields have no effect on intracellular
doxorubicin concentrations in all wild type and drug
resistant cell lines (Figure 4B, filled bars).
Discussion
ABC transporters provide vital protection from foreign
compounds by exporting these compounds from the cell,
thus lowering their intracellular concentration. Unfortu-
nately, exposure of cancer cells to chemotherapeutics,
mainly during relapse treatment, causes transporter
upregulation such that the resulting over-expression of
ABC transporters becomes one of the main causes of
treatment failure. Moreover, various tumors such as renal
cell, adrenocortical, colon and hepatocellular cancers
express ABCB1 and are practically chemoresistant [19].
To overcome this problem chemosensitizers that block
ABC transporter-mediated efflux were developed and
have been used to combat MDR. However, this approach
has not been clinically successful and therefore novel
approaches that bypass, rather than block ABC trans-
porters, are being sought for [20]. As the TTFields do not
affect drug transport (see Figure 4) they fall into this cate-
gory.
The results of this study clearly indicate that both the
MDR and WT cells are similarly sensitive to TTFields.
Moreover, TTFields were shown to enhance MDR cell
sensitivity to chemotherapeutic agents, so as to equal that
of WT cells under the same set of conditions (Figure 3).
This phenomenon can only be partially explained on the
basis of the corresponding dose - response curves (Figure
2) and the drug export rate (Figure 4). As demonstrated
Figure 3 Effects of doxorubicin and paclitaxel when applied sep-
arately and in combination with TTFields on the viability of wild 
type and MDR cells. A - MDA-MB-231 & MDA-MB-231/Dox; B - MCF-7 
& MCF-7/Mx; C - AA8 & EmtR1. Open bars - wild type cells; filled bars - 
MDR cell sub-lines. I & III - Separate exposures, II & IV - combined expo-
sures. TTFields intensity - 1.75 V/cm. Doxorubicin concentrations: A - 
0.04 μM; B - 0.5 μM; C - 0.6 μM. Paclitaxel concentrations: A - 5 nM; B -
0.1 μM; C - 0.1 μM. Treatment duration - 72 h. Data presented as mean 
± SEM of 24-36 replicate measurements from 3-5 experiments. * P < 
0.01, student t-test.
Table 2: Dose reduction indexes for MDR cell sub-lines 
treated alone and in combination with TTFields.
Dose reduction index (DRI)
Drug EmtR1 MCF-7/Mx MDA-MB-231/Dox
Doxorubicin 105 195 250
Paclitaxel 815 4404 > 10,000
The DRI estimates the extent to which the dose of one or more 
agents in the combination can be reduced to achieve effect levels 
that are comparable with those achieved with single agents. The 
effect of TTFields/drug combined treatment for each MDR cell 
sub-line was as shown in Figure 3. The same effect of single drug 
was obtained from dose-response curves (see Figure 2). The DRI 
was calculated as a ratio of drug concentrations used alone vs. 
drug concentrations used in combination with TTFields.
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cells is shifted to the right relative to the WT cells (see
also Figure 2). The magnitude of the shift is such that the
50% inhibition of WT cells that is obtained at a concen-
tration of 0.04 μM requires a concentration of 2.2 μM for
the MDR sub-line, i.e. a 55 fold higher concentration.
However, the data depicted in Figure 4 and correspond-
ing reports for low doxorubicin doses [21] indicate that
the drug export lowers the intracellular concentration
only by a factor of about 2. This means that some other
factors must be responsible for the MDR resistance that
corresponds to additional 20-30 fold drug concentration
change. From the data in Figure 3A we also learn that
both the MDR and WT cells are similarly highly sensitive
to combined chemotherapy - TTFields treatments. Thus,
while a 50% inhibition of MDR cells by doxorubicin alone
requires a concentration of 2.2 μM, the combined treat-
ment of TTFields and low concentration of doxorubicin
(0.0017 μM) is sufficient to induce a similar inhibition.
This is equivalent to an increased intracellular concentra-
tion of doxorubicin by a factor of over 1000. Thus,
TTFields seem to have effects specific to MDR cells, not
related to drug transport, that increase the MDR cell's
sensitivity to chemotherapy. This conclusion is consistent
with that of others [22-24] that attribute the MDR resis-
tance, in addition to reduced drug uptake, to a number of
potential mechanisms such as: sugar metabolism and
energy production, alterations in cytoskeletal elements,
microtubule and mitochondria distribution, etc. Within
the framework of the above suggested mechanisms [22-
24] it seems that the integrity of cytoskeleton and micro-
tubule as well as the mitochondria distribution may be
the most vulnerable to the forces produced by TTFields.
The former may be disrupted by particle movements
induced by the dielectrophoresis induced during
TTFields application [8] while the latter are highly polar
in themselves and are therefore directly subjected to the
alternating field forces.
Conclusions
The results of this study support the notion that TTFields
may be used, both as an effective stand alone anti-prolif-
eration agent for MDR cells, as well as an effective adju-
vant that enhances chemotherapy efficacy. Furthermore,
since TTFields are a physical modality, their therapeutic
efficacy is independent of interaction with cell receptors.
Therefore their efficacy is not expected to be limited to a
specific set of cell types [8-12]. On the basis of the above,
we believe that there is a high probability that TTFields
Figure 5 Effect of 72 h application of TTFields and chemothera-
peutic agents, separately and in combination on the viability of 
MDA-MB-231 wild type cells and MDA-MB-231/Dox MDR cells. -
- MDA-MB-231 cells treated with doxorubicin alone; -  - MDA-MB-
231 cells treated with doxorubicin in combination with TTFields (ref. 
[9]); -  - MDA-MB-231/Dox cells treated with doxorubicin alone.
Figure 4 Effect of TTFields on doxorubicin accumulation. A - Dose 
response curve for AA8 cells and for their MDR sub-line EmtR1. Open 
symbols - cells exposed to drug alone; filled symbols - cells exposed si-
multaneously to drug and TTFields. Circles - AA8 cell line; squares - 
EmtR1 sub line. Intensity of TTFields - 1.75 V/cm, frequency - 150 kHz. 
Treatment duration - 1 h. Data presented as means ± SEM of 16-24 rep-
licate measurements from 2-3 experiments. B - Effect of TTFields on 
doxorubicin accumulation by different MDR cell sub-lines relative to 
their parental wild type cell lines. Ordinate: relative intracellular doxo-
rubicin concentration in the drug resistant sub lines presented as % of 
the corresponding concentration in the wild type cells. Open bars - 
cells exposed to drug alone; filled bars - cells exposed simultaneously 
to drug and TTFields. Doxorubicin concentration: 30 μM. TTFields in-
tensity - 1.75 V/cm, TTFields frequency - 150 kHz. Treatment duration - 
1 h. Data are presented as mean ± SEM of 12-24 replicate measure-
ments from 3-4 experiments.
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wide range of human cancers including those that devel-
oped multi drug resistance.
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